

Notes of the Formulary Management Group

Held on	Tuesday 7 th June 2016			Jubilee House, Room 1	
Members	Attended	Apologies	Absent	Designation	Abbreviation
		✓		Prescribing Adviser	(PA)
		✓		Head of Medicines Management	(C)
	✓			GP (Trans) Vice Chair	(VC)
		✓		GP (North)	(GPN)
	✓			GP (West)	(GPW)
		✓		Patient Representative	(PR)
	✓			WHT Pharmacist	(WHTP)
	✓			Primary Care Pharmacist	(PCP)
		✓		DWMHPT Chief Pharmacist	(DWMHCP)
	✓			Healthcare Governance	(HG)
	✓			GP (South East)	(GPSE)
	✓			Clinical Nurse Specialist	(CNS)
		✓		Nurse Non-Medical Prescriber	(NNMP)
	✓			DWMHPT Deputy Pharmacist	(DWMHDP)
		✓		Medicine Optimisation Pharmacist	(MOP)
		✓		Note Taker	
	✓			Note Taker	
	✓			DWMH Consultant psychiatrist	
	✓			Lead Pharmacist – Walsall CCG	(LP)
	✓			SPR Cardiology	

	Agenda item	Actions
1	<p><u>Welcome And Apologises (Declarations of AOB)</u></p> <p>VC welcomed everyone to the June Formulary Management Group meeting.</p>	
2	<p><u>Minutes Of Last Meeting</u> - Consent agenda accepted.</p> <p>VC declared the minutes from Mays meeting were a true and accurate record.</p>	
3	<p><u>Matters Arising/Actions Sheet</u></p> <p>Degludec – Committee confirmed the audit has been done.</p> <p>Ferinject – CNS chased the Dr and confirms the audit has been completed but is still waiting to present it, which is due to take place at the next meeting on the 5th July.</p> <p>ABX Formulary – WHTP advised of no further updates but will come back to the committee in August with an update.</p> <p>NOACs - PCP advised the committee that the NOACs have now started and will be presenting a (Draft) starting document at the next meeting.</p> <p>KEELE Competency Training – Committee need to chase C for a date.</p> <p>Quarterly Declarations of Interest – PA sent forms out to all members and will need to be returned by the next meeting.</p> <p>Vortioxitene – DWMHDP advised the committee that the audit will be ready by August/September meeting.</p> <p>Baby Milks Formulary – CNS advised the committee that the guidelines are ready, just awaiting feedback from the paediatric nurses regarding information on preferred products – Should be completed by July.</p>	

Next Meeting – Tuesday 2nd August 2016, 1:00 – 3:30pm at Jubilee House, Room 1

Notes of the Formulary Management Group

	<p>Obesity Drugs - CNS agreed to chase.</p> <p>Renal Function and RAS Drug Combinations – Committee have received no further updates – Agreed to check with PA regarding progress update with the Cardiologists.</p> <p>OPEP Funding – Committee agreed action completed.</p> <p>Guanfacine (Revised ESCA) – DWMHDP to forward the revised ESCA onto MOP.</p> <p>Ceftobiprole to MMQT – WHTP advised the committee that the action is now completed.</p> <p>Drug Safety updates in newsletter – VC advised the committee that the action is now completed.</p>	
4	<p><u>Declarations of Interest</u></p> <p>Nothing was declared at the meeting.</p>	
5	<p><u>NICE Technology Appraisal</u></p> <p>Application no 128 Entresto – (SPR Cardiology Consultant) – A complex discussion took place with the committee about application 128, Entresto – The committee to agree a commissioning pathway and that this item would be brought back to a future JMMC. It was suggested to the SPR Cardiology Consultant that the multi-disciplinary heart failure specialist team should be responsible for the continue prescribing after the 28 day period – The committee agreed for the SPR Cardiology Consultant to bring back the application to the next meeting following a discussion with either a Cardiology consultant or heart failure nurse and the committee also asked for representation from either. In the meantime the item has been given a grey status on formulary, pending local arrangement.</p> <p>NICE TAG 390 – Canagliflozin, Dapagliflozin and Empagliflozin (Monotherapy) – WHTP advised the committee that no communication has been received from the Endocrinology & Diabetes Mellitus Consultant or his team regarding the NICE TAG 390 drug.</p>	
6	<p><u>Non NICE TA Drugs/devices – Full Applications</u></p> <p>None</p>	
7	<p><u>Non – NICE TA Drug/Devices - Short Applications</u></p> <p>Application no 126 – Gevoya – WHTP currently making enquiries with NHSE - As the commissioners have not issued a commissioning policy, there is only a draft on consultation that expires in August.</p> <p>Application no 127 – CalciD – Committee agreed to ask PA to put this drug on ScriptSwitch.</p> <p>Application no 130 – Rituximab – WHTP received an email from the Haematology Consultant (Unfortunately could not attend the meeting due to other commitments) explaining briefly about application 130, Rituximab which is due next summer – The committee agreed the application.</p>	
8	<p><u>Drugs Safety Update</u></p> <ul style="list-style-type: none"> • Letter sent to Healthcare professionals • Idelalisib (Zydelig ▼): Interim measures following signal of serious infection and deaths related to infection found in clinical trials. • Pomalidomide (Imnovid ▼): Risk of Hepatitis B reactivation. • BCR-ABL Tyrosine Kinase inhibitors: Risk of Hepatitis B reactivation. <p>A brief discussion took place with the committee regarding the drug safety updates, full details can be found in the folder.</p>	

Next Meeting – Tuesday 2nd August 2016, 1:00 – 3:30pm at Jubilee House, Room 1

Notes of the Formulary Management Group

9	<p><u>Horizon Scanning</u></p> <p>NICE Forward Planner – More information to follow.</p>	
10	<p><u>Appeals</u></p> <p>None</p>	
11	<p><u>Formulary Updates</u></p> <p>Adult ADHD shared care protocol – (DWMH Consultant Psychiatrist) – A complex discussion took place with the committee about Adult ADHD shared care protocol – The committee agreed that changes needed to be made regarding prescriptions; investigations and any associated mental health issues, should be directly referred to mental health. It was agreed that the DWMH Consultant Psychiatrist should speak to the commissioners to gain the necessary support and bring back the changes to the next meeting.</p>	
12	<p><u>Formulary Breach</u></p> <p>Insulin Pens Needles – (LP) – A short discussion took place regarding GPs receiving requests from patients who have been advised by district or community nurses to prescribe them Autosheild – VC agreed to contact the Head of Nursing for Community Team, to speak to the district nursing team.</p>	
13	<p><u>Recommendations to JMMC</u></p> <p>None</p>	
14	<p><u>Any Other Business</u></p> <p>Drug and Therapeutics Committee (FMG) ToR 2016</p> <p>KINES – Safer Prescribing DQIP</p> <p>KINES – Medicines – Related Burden</p> <p>KINES – DPP – 4 inhibitors and heart failure</p> <p>KINES – Monthly News Update</p> <p>BD Autosheild Needles – Following the breach discussion, PCP advised the committee about a previous discussion regarding brand prescribing for anti-epileptic drugs, it was agreed that branded or brand generic drugs be issued. PCP continued by saying several cases whereby patients who have been seen by the new nurse are being switched from Lamotrigine to Lamictal. The nurse has been informally invited to the committee meeting to provide evidence that the Lamictal brand is the required forward treatment and for what reason.</p>	
15	<p>Finish</p>	<p>14:20</p>
<p>These minutes are a true representation of the Group's proceeding</p> <p>Signed: _____ Chair _____ Date _____</p>		

These minutes will be redacted to remove names/initials before publication

Next Meeting – Tuesday 2nd August 2016, 1:00 – 3:30pm at Jubilee House, Room 1

Notes of the Formulary Management Group

Future Meeting Dates

Formulary Management Group Future Meeting Schedule 2016								
Date	Month	Year	Venue		Date	Month	Year	Venue
					2 nd	August	2016	Room1
					6 th	September	2016	Room1
					4 th	October	2016	Room1
					1 st	November	2016	Room1
					6 th	December	2016	Room1

Formulary Management Group Future Meeting Schedule 2017								
Date	Month	Year	Venue		Date	Month	Year	Venue
3 rd	January	2017	Room1		4 th	July	2017	Room1
7 th	February	2017	Room1		1 st	August	2017	Room1
7 th	March	2017	Room1		5 th	September	2017	Room1
4 th	April	2017	Room1		3 rd	October	2017	Room1
2 nd	May	2017	Room1		7 th	November	2017	Room1
6 th	June	2017	Room1		5 th	December	2017	Room1

Formulary Management Group Future Meeting Schedule 2018								
Date	Month	Year	Venue		Date	Month	Year	Venue
2 nd	January	2018	Room1		3 rd	July	2018	Room1
6 th	February	2018	Room1		7 th	August	2018	Room1
6 th	March	2018	Room1		4 th	September	2018	Room1
3 rd	April	2018	Room1		2 nd	October	2018	Room1
1 st	May	2018	Room1		6 th	November	2018	Room1
5 th	June	2018	Room1		4 th	December	2018	Room1

Next Meeting – Tuesday 2nd August 2016, 1:00 – 3:30pm at Jubilee House, Room 1